For instance, a study in a small cohort of 39 patients with advanced lung cancer demonstrated that individuals with decreased α1,3-fucosylated α1-acid glycoprotein (AGP) serum levels after treatment with nivolumab had better 2-year survival than those whose levels remained consistently high [25]. This evidence concerns the gene ATP5MK and lung carcinoma.